



Dear contributors, colleagues and co-workers,

With Christmas and the end of 2021 approaching, the inclusion into the SENOMAC trial also draws to a close. Despite many challenges especially during the covid-19 pandemic, you all have shown enormous efforts and dedication to the trial and our patients and I wish to thank you for a fantastic collaboration. Until this morning, 2754 patients have been randomised into the trial! After deduction of 223 early drop-outs, we have a sample of 2531 individuals included which is simply marvellous.

As you know, the enrolment target was 3000 patients and you might wonder whether this trial will be another in the line of underpowered de-escalation trials. Since statistical power is not based on the number of included individuals but on the number of events (in our case, all-cause death), and with current numbers and estimated developments, we expect that power for the primary endpoint overall survival will be reached within 2-3 years of follow-up.

Some of you have wondered how to perform follow-up visits in the times of the pandemic. Since it is not recommendable to physically meet patients if not strictly necessary considering the risk of transmission of the corona virus, it is entirely fine to have a telephone call with your patient instead of a physical visit. I trust your departmental routines and clinical judgment to also in the next years adapt to the situation so that the best for the patient is always in focus.


**Please do remember that no patients should be signing any informed consent forms after December 31, 2021. The randomisation system ALEA will be remaining open until January 31, 2022 but only for patients giving their consent before December 31, 2021. After that date, no randomisation into the SENOMAC trial is possible anymore.**

You can find current randomisation figures with you on the following pages. Please do share this newsletter with your team.

Now I wish you a Merry Christmas and a happy, healthy and less pandemic-stricken New Year.

Jana de Boniface,  
for the SENOMAC steering committee and the sponsor Karolinska Institutet.

1. Number of randomisations per month



2. Cumulative number of randomisations since start of trial




Table: Number of site-specific randomisations as of **December 20, 2021**

**Please observe that this table only shows those sites that have generated randomisations as of 2021DEC20. For a list of all initiated sites, please see the trial homepage.**

Site	Country	Initiation visit	First patient in	Number of randomisations
Karolinska	Sweden	2015-01-30	2015-02-27	124
Västerås	Sweden	2015-03-02	2015-04-14	63
S:t Göran	Sweden	2015-03-05	2016-06-07	192
Akademiska Uppsala	Sweden	2015-03-12	2016-02-14	48
Södersjukhuset	Sweden	2015-03-18	2015-11-24	161
Örebro	Sweden	2015-03-25	2015-10-01	57
Sahlgrenska	Sweden	2015-04-23	2015-06-10	113
Lund/Malmö	Sweden	2015-05-13	2015-10-13	133
Helsingborg	Sweden	2015-05-20	2015-07-23	71
Linköping	Sweden	2015-05-27	2016-11-03	112
Karlstad	Sweden	2015-05-28	2015-12-14	45
Skaraborg	Sweden	2015-06-04	2015-10-22	92
Uddevalla	Sweden	2015-06-04	2015-09-21	24
Kalmar	Sweden	2015-09-02	2016-03-03	24
Västervik	Sweden	2015-09-02	2016-02-18	34
Karlskrona	Sweden	2015-09-03	2015-12-14	8
Gävle	Sweden	2015-09-10	2015-12-30	52
Sundsvall	Sweden	2015-10-15	2015-10-29	72
Umeå	Sweden	2015-11-19	2016-02-10	68
Halmstad/Varberg	Sweden	2015-12-10	2016-02-17	34
Växjö	Sweden	2016-01-14	2016-03-23	44
Aarhus	Denmark	2016-11-28	2017-04-25	141
Randers	Denmark	2017-09-14	2017-11-07	18
Köpenhamn Rigshospitalet/Herlev	Denmark	2016-12-19	2017-04-20	288
Jönköping	Sweden	2017-01-20	2017-11-13	46
Kristianstad	Sweden	2017-03-20	2017-05-17	50
Borås	Sweden	2017-02-20	2018-09-14	10
Aabenraa	Denmark	2017-10-12	2017-12-13	80
Odense	Denmark	2017-11-22	2018-02-16	53
Esbjerg	Denmark	2017-12-12	2018-03-05	16
Viborg	Denmark	2017-11-03	2018-03-16	110
Aalborg	Denmark	2017-10-10	2018-02-07	100
Bad Langensalza	Germany	2018-04-04	2018-05-23	5
Rostock	Germany	2018-03-12	2018-06-07	16
Berlin Spandau	Germany	2018-04-19	2018-09-07	4
Laiko 1, Athens	Greece	2018-06-28	2018-10-12	19

Vejle	Denmark	2018-03-19	2018-11-07	67
Esslingen	Germany	2018-02-16	2018-10-26	2
Klinikum Kassel	Germany	2018-06-12	2018-11-22	1
Heraklion, Crete	Greece	2019-02-19	2019-03-07	9
Athens Euroclinic	Greece	2019-12-11	2019-02-12	14
Dresden	Germany	2018-05-02	2019-03-01	7
Hanau	Germany	2018-05-18	2019-02-12	14
Karlsruhe	Germany	2018-07-11	2018-12-18	1
Villingen-Schwenningen	Germany	2018-09-10	2018-12-28	1
Mittelbaden	Germany	2018-08-16	2019-03-13	4
Laiko 2, Athens	Greece	2018-11-07	2019-05-29	4
San Raffaele Milano	Italy	2018-02-01	2019-05-21	8
IEO Milano	Italy	2019-05-06	2019-06-06	27
Unna	Germany	2018-03-01	2019-05-28	6
Ebersberg	Germany	2018-04-10	2019-04-06	2
Stendal	Germany	2018-04-25	2019-05-14	1
Wiesbaden St. Josef	Germany	2018-06-14	2019-05-03	1
Worms	Germany	2018-08-28	2019-05-02	2
Potsdam	Germany	2019-06-18	2019-07-01	7
Tübingen	Germany	2019-09-04	2019-09-24	12
Böblingen	Germany	2018-07-10	2019-11-07	5
Wiesbaden Asklepios	Germany	2019-11-27	2020-01-28	6
Dresden St. Joseph	Germany	2019-10-08	2020-05-18	1
Bochum	Germany	2018-02-07	2020-05-05	4
Helena Venizelou	Greece	2020-07-30	2020-09-18	3
Brescia	Italy	2020-01-20	2020-11-23	5
Schkeuditz	Germany	2018-07-06	2020-12-11	2
Bietigheim	Germany	2020-09-11	2020-12-16	2
Attikon	Greece	2020-06-12	2021-01-22	5
Trento	Italy	2021-07-05	2021-07-09	2
Napoli	Italy	2021-08-15	2021-09-23	2
<b>Total</b>				<b>2754</b>

Figure: Accumulated site-specific inclusion (only sites generating randomisations as of **December 20, 2021** are shown).

